Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960571 | 0.95 | PSMB5 (0.43) | PDGFRBPDGFRACYP2A6PTK2PSMB5 | |
| SCHEMBL13778365 | 0.78 | PSMB5 (0.48) | PDGFRBPDGFRACYP2A6PSMB5PPARA | |
| SCHEMBL4150712 | 0.75 | HTR2C (0.61) | PTK2 | |
| SCHEMBL31149504 | 0.75 | HTR2C (0.61) | PTK2 | |
| SCHEMBL16135140 | 0.74 | HTR1A (0.41) | PDGFRBPDGFRAPSMB5PPARACYP11B2 | |
| SCHEMBL5387785 | 0.74 | PSMB5 (0.38) | PDGFRBPDGFRAPSMB5PPARAACMSD | |
| SCHEMBL17820514 | 0.74 | CYP2A6 (0.42) | PDGFRBPDGFRACYP2A6PSMB5PPARA | |
| SCHEMBL13778361 | 0.73 | PSMB5 (0.54) | PDGFRBPDGFRACYP2A6PSMB5CYP11B2 | |
| SCHEMBL25348846 | 0.72 | CYP2A6 (0.44) | CYP2A6PTK2CYP11B1CYP11B2PTGS2 | |
| SCHEMBL14392676 | 0.72 | CYP2A6 (0.61) | CYP2A6PTK2CYP11B1CYP11B2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7235568-B2 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-06-26 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-7163957-B2 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2007-01-16 | — | — | US | disclosed |
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1551821-B1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | PIERRE FABRE MEDICAMENT (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1551821-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035561-A1 | 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264471-A1 | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia | CNR2, CNR1, DBH | PDGFRB 4681/4885PDGFRA 4514/4885CYP2A6 366/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PDGFRB 221/4885PDGFRA 100/4885CYP2A6 1045/4885 |
| US-20060014827-A1 | 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | CHRNA3, CHRNB3, CNR2 | PDGFRB 4812/4885PDGFRA 4723/4885CYP2A6 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.